Skip to main content
Erschienen in: Wiener klinisches Magazin 2/2019

19.02.2019 | Pathologie

Nichtkleinzelliges Lungenkarzinom – Pathologie und Biologie

verfasst von: Dr. Maike Wittersheim, Dr. Simon Schallenberg, Univ.-Prof. Dr. Reinhard Büttner

Erschienen in: Wiener klinisches Magazin | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Nichtkleinzellige Lungenkarzinome (NSCLC) machen ca. 75 % der malignen epithelialen Lungentumoren aus. In den vergangenen Jahren konnten profunde Erkenntnisse über molekulare Mechanismen der Krebsentstehung der Lunge gewonnen werden und in der Folge zielgerichtete Substanzen („targeted drugs“) und immuntherapeutisch wirksame Medikamente entwickelt werden. Diese Fortschritte haben den Ablauf der pathologischen Diagnostik maßgeblich beeinflusst.

Ziel

Der vorliegende Artikel soll einen Überblick über die häufigsten histologischen Subtypen der NSCLC, ihre morphologischen, immunhistochemischen und molekularpathologischen Charakteristika geben.

Material und Methoden

Eine selektive Literaturrecherche der Datenbank Pubmed wurde durchgeführt.

Ergebnisse und Diskussion

Adenokarzinome, Plattenepithelkarzinome und großzellige Karzinome sind die häufigsten histologischen Subtypen. Durch die in der pathologischen Routine verfügbaren Zusatzuntersuchungen lassen sich in der Regel auch gering differenzierte Tumoren gut zuordnen. NSCLC zeigen eine Reihe genetischer Veränderungen, therapeutisch nutzbar sind Alterationen von EGFR, MET, ALK1 und ROS1.
Literatur
1.
Zurück zum Zitat Aredo JV, Padda SK (2018) Management of KRAS-mutant non-small cell lung cancer in the era of precision medicine. Curr Treat Options Oncol 19:43CrossRef Aredo JV, Padda SK (2018) Management of KRAS-mutant non-small cell lung cancer in the era of precision medicine. Curr Treat Options Oncol 19:43CrossRef
2.
Zurück zum Zitat Barbareschi M, Cantaloni C, Del Vescovo V et al (2011) Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 136:773–782CrossRef Barbareschi M, Cantaloni C, Del Vescovo V et al (2011) Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 136:773–782CrossRef
3.
Zurück zum Zitat Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870CrossRef Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870CrossRef
4.
Zurück zum Zitat Boland JM, Froemming AT, Wampfler JA et al (2016) Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma--analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. Hum Pathol 51:41–50CrossRef Boland JM, Froemming AT, Wampfler JA et al (2016) Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma--analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. Hum Pathol 51:41–50CrossRef
5.
Zurück zum Zitat Bubendorf L, Buttner R, Al-Dayel F et al (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489–503CrossRef Bubendorf L, Buttner R, Al-Dayel F et al (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489–503CrossRef
6.
Zurück zum Zitat Camidge DR, Kono SA, Flacco A et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581–5590CrossRef Camidge DR, Kono SA, Flacco A et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581–5590CrossRef
7.
Zurück zum Zitat Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519–525CrossRef Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519–525CrossRef
8.
Zurück zum Zitat Clinical Lung Cancer Genome Project, Network Genomic Medicine (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153 Clinical Lung Cancer Genome Project, Network Genomic Medicine (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153
9.
Zurück zum Zitat Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040–4045CrossRef Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040–4045CrossRef
10.
Zurück zum Zitat Dearden S, Stevens J, Wu YL et al (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24:2371–2376CrossRef Dearden S, Stevens J, Wu YL et al (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24:2371–2376CrossRef
11.
Zurück zum Zitat Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T‑cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800CrossRef Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T‑cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800CrossRef
12.
Zurück zum Zitat Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850–859CrossRef Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850–859CrossRef
13.
Zurück zum Zitat Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034CrossRef Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034CrossRef
14.
Zurück zum Zitat Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865–875CrossRef Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865–875CrossRef
15.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRef Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRef
16.
Zurück zum Zitat Joshi A, Zanwar S, Noronha V et al (2017) EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther 10:1859–1863CrossRef Joshi A, Zanwar S, Noronha V et al (2017) EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther 10:1859–1863CrossRef
17.
Zurück zum Zitat Jucker M, Gunther A, Gradl G et al (1994) The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 18:7–16CrossRef Jucker M, Gunther A, Gradl G et al (1994) The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 18:7–16CrossRef
18.
Zurück zum Zitat Lewis DR, Check DP, Caporaso NE et al (2014) US lung cancer trends by histologic type. Cancer 120:2883–2892CrossRef Lewis DR, Check DP, Caporaso NE et al (2014) US lung cancer trends by histologic type. Cancer 120:2883–2892CrossRef
19.
Zurück zum Zitat Mcleer-Florin A, Moro-Sibilot D, Melis A et al (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348–354CrossRef Mcleer-Florin A, Moro-Sibilot D, Melis A et al (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348–354CrossRef
20.
Zurück zum Zitat Park S, Choi YL, Sung CO et al (2012) High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27:197–207PubMed Park S, Choi YL, Sung CO et al (2012) High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27:197–207PubMed
21.
Zurück zum Zitat Rekhtman N, Tafe LJ, Chaft JE et al (2013) Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 26:511–522CrossRef Rekhtman N, Tafe LJ, Chaft JE et al (2013) Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 26:511–522CrossRef
22.
Zurück zum Zitat Reungwetwattana T, Liang Y, Zhu V et al (2017) The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer 103:27–37CrossRef Reungwetwattana T, Liang Y, Zhu V et al (2017) The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer 103:27–37CrossRef
23.
Zurück zum Zitat Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203CrossRef Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203CrossRef
24.
Zurück zum Zitat Sasaki T, Rodig SJ, Chirieac LR et al (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46:1773–1780CrossRef Sasaki T, Rodig SJ, Chirieac LR et al (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46:1773–1780CrossRef
25.
Zurück zum Zitat Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29:1165–1172CrossRef Scheel AH, Dietel M, Heukamp LC et al (2016) Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29:1165–1172CrossRef
26.
Zurück zum Zitat Schildhaus HU, Schultheis AM, Ruschoff J et al (2015) MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 21:907–915CrossRef Schildhaus HU, Schultheis AM, Ruschoff J et al (2015) MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 21:907–915CrossRef
27.
Zurück zum Zitat Shepherd FA, Domerg C, Hainaut P et al (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31:2173–2181CrossRef Shepherd FA, Domerg C, Hainaut P et al (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31:2173–2181CrossRef
28.
Zurück zum Zitat Sholl LM, Aisner DL, Varella-Garcia M et al (2015) Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 10:768–777CrossRef Sholl LM, Aisner DL, Varella-Garcia M et al (2015) Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 10:768–777CrossRef
29.
Zurück zum Zitat Surati M, Patel P, Peterson A et al (2011) Role of MetMAb (OA-5D5) in c‑MET active lung malignancies. Expert Opin Biol Ther 11:1655–1662CrossRef Surati M, Patel P, Peterson A et al (2011) Role of MetMAb (OA-5D5) in c‑MET active lung malignancies. Expert Opin Biol Ther 11:1655–1662CrossRef
30.
Zurück zum Zitat Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143–3149CrossRef Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143–3149CrossRef
31.
Zurück zum Zitat Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285CrossRef Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285CrossRef
32.
Zurück zum Zitat Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart. 4th edition. International Agency for Research on Cancer, IARC, Lyon Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart. 4th edition. International Agency for Research on Cancer, IARC, Lyon
33.
Zurück zum Zitat Vassella E, Langsch S, Dettmer MS et al (2015) Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type? Oncotarget 6:23905–23916CrossRef Vassella E, Langsch S, Dettmer MS et al (2015) Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type? Oncotarget 6:23905–23916CrossRef
34.
Zurück zum Zitat Weissferdt A (2014) Large cell carcinoma of lung: on the verge of extinction? Semin Diagn Pathol 31:278–288CrossRef Weissferdt A (2014) Large cell carcinoma of lung: on the verge of extinction? Semin Diagn Pathol 31:278–288CrossRef
35.
Zurück zum Zitat Wennerberg K, Rossman KL, Der CJ (2005) The Ras superfamily at a glance. J Cell Sci 118:843–846CrossRef Wennerberg K, Rossman KL, Der CJ (2005) The Ras superfamily at a glance. J Cell Sci 118:843–846CrossRef
36.
Zurück zum Zitat Yoshida A, Tsuta K, Watanabe S et al (2011) Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72:309–315CrossRef Yoshida A, Tsuta K, Watanabe S et al (2011) Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72:309–315CrossRef
37.
Zurück zum Zitat Yoshizawa A, Motoi N, Riely GJ et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–664CrossRef Yoshizawa A, Motoi N, Riely GJ et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–664CrossRef
38.
Zurück zum Zitat Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985–78993PubMedPubMedCentral Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985–78993PubMedPubMedCentral
Metadaten
Titel
Nichtkleinzelliges Lungenkarzinom – Pathologie und Biologie
verfasst von
Dr. Maike Wittersheim
Dr. Simon Schallenberg
Univ.-Prof. Dr. Reinhard Büttner
Publikationsdatum
19.02.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 2/2019
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-019-0277-y

Weitere Artikel der Ausgabe 2/2019

Wiener klinisches Magazin 2/2019 Zur Ausgabe

Panorama

Panorama